Results of Transurethral Resection Plus Adjuvant Intravesical Chemotherapy for Superficial Bladder Cancer

Background: We analyzed the results of conservative therapy for superficial bladder cancer to determine the risk factors for recurrence and progression.

[1]  R. Greenberg,et al.  Intravesical therapy for superficial bladder cancer. , 2000, Oncology.

[2]  L. Sobin,et al.  Histological Typing of Urinary Bladder Tumours , 1999, International Histological Classification of Tumours.

[3]  A. Gotoh,et al.  Clinical Evaluation of Random Biopsy of Urinary Bladder in Patients with Superficial Bladder Cancer , 1998, International journal of urology : official journal of the Japanese Urological Association.

[4]  W. Fair,et al.  The treated natural history of high risk superficial bladder cancer: 15-year outcome. , 1997, The Journal of urology.

[5]  E. Holmberg,et al.  The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. , 1997, The Journal of urology.

[6]  M. Parmar,et al.  The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. , 1996, The Journal of urology.

[7]  H. Minakami,et al.  [Clinical assessment for prognostic factors related to recurrence and progression in superficial bladder cancer]. , 1995, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[8]  D. Lamm,et al.  INTRAVESICAL CHEMOTHERAPY AND IMMUNOTHERAPY: HOW DO WE ASSESS THEIR EFFECTIVENESS AND WHAT ARE THEIR LIMITATIONS AND USES? , 1995, International journal of urology : official journal of the Japanese Urological Association.

[9]  P. Schellhammer,et al.  Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG. , 1993, Urology.

[10]  M. Melekos,et al.  Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. , 1993, The Journal of urology.

[11]  N. Heney,et al.  Natural history of superficial bladder cancer. Prognostic features and long-term disease course. , 1992, The Urologic clinics of North America.

[12]  Max H. Myers,et al.  Manual for Staging of Cancer , 1992 .

[13]  P. Schellhammer,et al.  Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer. , 1992, The Journal of urology.

[14]  N. Christensen,et al.  Grading of human urothelial carcinoma based on nuclear atypia and mitotic frequency. II. Prognostic importance. , 1991, The Journal of urology.

[15]  C. Bouffioux.  Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group. , 1991, Scandinavian journal of urology and nephrology. Supplementum.

[16]  Y. Matsumura.  Cooperative Study of Therapy of Superficial Bladder Cancer by Intravesical Instillation of Pirarubicin , 1990, American Journal of Clinical Oncology.

[17]  J. Sheinfeld,et al.  The T1 bladder tumor. , 1990, Seminars in urology.

[18]  H. Huland,et al.  Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. , 1990, The Journal of urology.

[19]  D. Lamm,et al.  Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. , 1989, The Journal of urology.

[20]  P. Abel,et al.  Should pT1 transitional cell cancers of the bladder still be classified as superficial? , 1988, British journal of urology.

[21]  D. Lamm.  Bacillus Calmette-Guerin immunotherapy for bladder cancer. , 1985, The Journal of urology.

[22]  M. Soloway.  The Management of Superficial Bladder Cancer , 1980, Cancer.

[23]  M. Soloway.  Rationale for intensive intravesical chemotherapy for superficial bladder cancer. , 1980, The Journal of urology.

[24]  D. Carr.  The manual for the staging of cancer. , 1977, Annals of internal medicine.